On Aug. 30, 2023, the Department of Health and Human Services, the Department of Labor, and the Department of the Treasury issued the proposed rule titled “Requirements Related to the Mental Health Parity and Addiction Equity Act. AMCP submitted comments in response to the proposed rule on Oct. 17.
With October devoted to National Pharmacy Awareness, AMCP CEO Susan Cantrell talks about the outstanding efforts of managed care pharmacists across the United States in her latest blog.
The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) today announced that it has been awarded a $1.4 million grant from the Food & Drug Administration (FDA) to enable biosimilar research.
On August 21, 2023, CMS Issued the Maximum Monthly Cap on Cost-Sharing Payments Under Prescription Drug Plans: Draft Part One Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025. The purpose of this document is to provide interested parties with draft part one guidance on a select set of topics for the Maximum Monthly Cap on Cost-Sharing Payments Program.
On June 22, CMS unveiled proposed guidance titled "Coverage with Evidence Development." Given AMCP's commitment to addressing health disparities in medication use and access, AMCP submitted comments in response to the proposed guidance on Aug. 21.
AMCP applauds the 10th Circuit for protecting the vital functions of ERISA & Medicare Part D, which provide essential services to workers and seniors, in yesterday’s ruling in the case of @PCMA v. Glen Mulready.
From best practices in managing obesity to the latest and greatest in gene and cell therapies, guest blogger Steve Kheloussi highlights three reasons he will be attending AMCP eLearning Day.
In her latest blog, AMCP CEO Susan Cantrell recaps our inaugural workshop on the IRA, reinforcing that there is still a great deal of uncertainty as key milestones approach. Learn how AMCP is addressing concerns this landmark legislation is causing across managed care pharmacy and the larger healthcare industry.
On July 25, 2023, AMCP commented on the Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program [CMS-2434-P].
In June, AMCP hosted the Deep Dive into Prescription Digital Therapeutics Summit, convening expert panelists and attendees from across the industry. Read 10 key takeaway points from the Summit.